Allergy & Immunology
COHORT
● Cohort
Review suggests chemokine inhibition as prospective therapeutic target for atopic dermatitis
Frontiers in Medicine
Published March 31, 2026
DOI ↗
This review article synthesizes basic and clinical research on the role of chemokines in atopic dermatitis (AD). The analysis, which included studies in patients with AD and AD model mice, found that lesional skin tissues highly express various chemokines and that chemokine ligand-receptor interactions enhance immune cell migration. The review reports that inhibition and blockade of these pathways contribute to the regulation of the inflammatory response in AD, with some blocking agents and antagonists showing positive results in improving inflammatory phenotypes in AD model mice. No specific effect sizes, absolute numbers, or statistical measures were reported for these findings. Safety and tolerability data for these interventions were not reported in the review. Key limitations include the nature of the evidence as a review summarizing existing research rather than presenting new clinical trial data. The practice relevance is restrained, as the authors note chemokine ligands and/or receptors are prospective targets for AD therapy, but clinical trials are described as progressing slowly and steadily, with no human efficacy or safety results available from this review.
Researchers reviewed existing studies to understand the role of chemokines in atopic dermatitis, commonly known as eczema. Chemokines are signaling molecules that guide immune cells. The review found that these molecules are highly active in skin affected by eczema, helping to draw immune cells into the area and worsen inflammation.
The research looked at studies involving people with eczema and mice with a similar condition. In mouse studies, some experimental drugs that block these chemokine pathways showed positive results in reducing skin inflammation. This suggests that targeting these pathways could be a new way to treat eczema.
No safety information from human trials was reported in this review. The main reason for caution is that this is not a new experiment, but a summary of past research. While the idea is promising and human trials are slowly progressing, there are no results yet showing how well or how safely these potential treatments work in people. Readers should see this as an explanation of an active area of scientific investigation, not a report on a ready-to-use therapy.
What this means for you: Early research points to a new eczema treatment approach, but human trials are still underway.
View Original Abstract ↓
Atopic dermatitis (AD) is a chronic inflammatory skin disease that commonly causes eczema accompanied by severe itching on pathological skin lesions. Although the pathological mechanisms are not fully understood, epidermal barrier dysfunction and immune dysfunction are critical for the development of AD. Notably, skin-infiltrating immune cells play a crucial role in the development of atopic skin inflammation. Recent studies have demonstrated that the infiltration of inflammatory cells into skin lesion is regulated by various chemokine ligands-receptors interactions. In this review, we focused on the pathogenic role of chemokines and chemokine receptors in AD development. The lesional skin tissues of patients with AD highly express various chemokines to enhance the migration of immune cells via chemokine ligand-receptor interactions. Since thier the inhibition and blockade contribute to the regulation of inflammatory response in the lesional skins of AD, chemokine ligands and/or receptors are prospective targets for AD therapy. In fact, some blocking agents and antagonist have shown positive results in the improvement of the inflammatory phenotypes in AD model mice. Clinical trials are progressing slowly but steadily, suggesting that chemokine ligands-receptors interactions remain a prospective therapeutic target for AD.
